[1] 宋杰, 陈凤格, 赵伟, 等. 胃癌的发病率现状与治疗研究进展[J]. 中国慢性病预防与控制,2016,24(9):704-707. [2] Dilege E, Mihmanli M, Demir U, et al.Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer[J]. Hepatogastroenterology,2010,57(99-100):674-677. [3] Gong YH, Sun LP, Yuan Y.Evaluation of serum pepsinogen Ⅰ, Ⅱ and osteopontin co-detection in gastric cancer screening[J]. Zhonghua Zhong Liu Za Zhi,2006, 28(9):691-693. [4] Furger KA, Allan AL, Wilson SM, et al.Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin[J]. Mol Cancer Res,2003,1(11):810-819. [5] 章华础, 萧祥熊. 组织多肽特异性抗原检测及其临床应用[J]. 放射免疫学杂志,2007,20(4):339-342. [6] Shimada H, Noie T, Ohashi M, et al.Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association[J]. Gastric Cancer,2014,17(1):26-33. [7] 付生弟, 谢辉. 肿瘤标志物CEA、CA19-9、CA72-4及CA242在胃癌诊断及预后判断中的应用价值[J]. 标记免疫分析与临床,2016,23(4):428-430. [8] 陈平, 俞骁珺, 谷雷雷, 等. 信号转导与转录激活蛋白活化抑制蛋白1的表达与胃癌微环境转移结构关系及预后[J]. 内科理论与实践,2017,12(6):365-370. [9] Chen T, Sun L, He C, et al.Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors[J]. PLoS One,2014,9(12):e114005. [10] 阎欣, 李萍, 王丽卓, 等. 血清OPN、CEA、CA199检测在胃癌中的临床意义[J]. 环球中医药,2015,8(s2):75-77. [11] Gu X, Gao XS, Ma M, et al.Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis[J]. Oncotarget,2016,7(43):69666-69673. [12] Treska V, Topolcan O, Stanislav K, et al.Preoperative tumor markers as prognostic factors of colorectal liver metastases[J]. Hepatogastroenterology,2009,56(90):317-320. [13] Sandblom G, Granroth S, Rasmussen IC.TPS, CA19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head[J]. Ups J Med Sci,2008,113(1):57-64. [14] 武新洋, 张欢, 潘自来, 等. 双源CT对原发性胃淋巴瘤和进展期胃癌的鉴别诊断价值[J]. 诊断学理论与实践,2018,17(1):60-65. |